Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Thrombin Clear all
Completed Phase 4 Interventional Results available

The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery

NCT01235715
View directory record Official record
Conditions
Osteoarthritis
Interventions
Evicel fibrin sealant
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
20 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

NCT00116012
View directory record Official record
Conditions
Coronary Disease
Interventions
rNAPc2
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

NCT01754480
View directory record Official record
Conditions
Parenchymous Tissue Surgical Bleeding
Interventions
Fibrin Sealant Grifols, Surgicel®
Biological · Device
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Not listed
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Loma Linda, California • Los Angeles, California • New Haven, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Dose Finding Study of HP802-247 in Venous Leg Ulcers

NCT00852995
View directory record Official record
Conditions
Venous Leg Ulcer, Venous Stasis Ulcers
Interventions
HP802-247, Placebo (Vehicle)
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
29
States / cities
Tucson, Arizona • Castro Valley, California • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

FS VH S/D 500 S-apr in Vascular Surgery

NCT00892957
View directory record Official record
Conditions
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Interventions
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Surgical gauze pads
Biological · Other
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Not listed
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Sep 12, 2026, 2:17 AM EDT
Completed No phase listed Observational

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

NCT05548777
View directory record Official record
Conditions
Anticoagulant-related Major Bleed
Interventions
Andexanet alfa, 4F-PCC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Agoura Hills, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

NCT02889562
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 12, 2026, 2:17 AM EDT
Recruiting Phase 2 Interventional

A Study of Isoquercetin in People With Ovarian Cancer

NCT07303894
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Serous Ovarian Tumor
Interventions
Isoquercetin, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery

NCT04660721
View directory record Official record
Conditions
Hemostasis, General Surgery
Interventions
sFilm-FS, TACHOSIL®
Combination Product
Lead sponsor
Sealantium Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

NCT00803101
View directory record Official record
Conditions
Reversal of Coagulopathy
Interventions
Beriplex® P/N (Kcentra), Fresh frozen plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Newark, Delaware • Lexington, Kentucky • Boston, Massachusetts + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2015 · Synced Sep 12, 2026, 2:17 AM EDT
Terminated No phase listed Observational

Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle

NCT00178542
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

NCT00990288
View directory record Official record
Conditions
Blood Loss
Interventions
Hemostatic Matrix
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 12, 2026, 2:17 AM EDT
Recruiting No phase listed Observational

Evaluation of Hemostasis in Bleeding and Thrombotic Disorders

NCT00178594
View directory record Official record
Conditions
Blood Coagulation Disorders, Inherited, Thrombotic Disorder
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 98 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2028
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 12, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

NCT03003390
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

NCT02239120
View directory record Official record
Conditions
Stroke, Secondary Prevention
Interventions
optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 150 Years
Enrollment
5,390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
110
States / cities
Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 12, 2026, 2:17 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

NCT07094087
View directory record Official record
Conditions
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions
BE1116, FFP
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Early Phase 1 Interventional

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

NCT05281718
View directory record Official record
Conditions
Hemophilia A
Interventions
Factor IX
Drug
Lead sponsor
Tulane University
Other
Eligibility
12 Years to 120 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

NCT03453060
View directory record Official record
Conditions
Thrombosis
Interventions
E-WE Thrombin- Dose 1, E-WE Thrombin- Dose 2, E-WE Thrombin- Dose 3, E-WE Thrombin- Dose 4, Placebo
Drug · Other
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Fibrin Sealant for the Sealing of Dura Sutures

NCT00681824
View directory record Official record
Conditions
Pathological Processes in the Posterior Fossa, Dura Defects
Interventions
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Standard of care
Biological · Procedure
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
3 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
12
States / cities
Duarte, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants

NCT00859547
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
rThrombin, 1000 IU/mL
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 12, 2026, 2:17 AM EDT
Completed No phase listed Observational

Study to Determine the Accuracy of Prothrombin Time of Warfarinised Blood

NCT01375725
View directory record Official record
Conditions
Clotting Disorders
Interventions
Not listed
Lead sponsor
Universal Biosensors Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Batesville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Argatroban Stroke Treatment - A Pilot Safety Study

NCT00268762
View directory record Official record
Conditions
Ischemic Stroke
Interventions
argatroban
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 12, 2026, 2:17 AM EDT
Withdrawn Not applicable Interventional

Pneumostasis With Use of Bio-absorbable Mesh and Fibrin Sealant in Lung Resection

NCT04317924
View directory record Official record
Conditions
Air Leak From Lung
Interventions
Polyglycolic acid felt, Standard of care
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 12, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

The Fibrin Patch Soft Tissue Study

NCT00658723
View directory record Official record
Conditions
Hemostasis
Interventions
Fibrin Pad, SURGICEL™
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Sep 12, 2026, 2:17 AM EDT